Onsdag 16 September | 12:50:22 Europe / Stockholm
Svenska | English

All ägardata du vill ha finns i Holdings!

BioPorto: First patient enrolled in ProNephro NGAL validation trial

2026-09-16 12:02:00

DNB Carnegie has published a new flash comment on BioPorto following recent news flow.

To access the full report and subscribe to future updates, visit https://access.dnbcarnegie.com/companies/1630

Information
This is a press release from DNB Carnegie. For information about DNB Carnegie commissioned research, see https://access.dnbcarnegie.com/, or contact our commissioned research team at [email protected].

About Us
DNB Carnegie is the leading and independent Nordic investment and private bank. Our operations within Corporate Finance, Securities and Research, Private Banking and Wealth Management are among the market leaders within their respective sectors. Together, they build an unbeatable combination of integrated knowledge, guiding our clients towards better business. DNB Carnegie operates in six countries and has more than 800 employees.

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Företag
Pressmeddelanden